In summary, we report therapeutic synergy of NKTR-214 with PD-1 and CTLA-4 CPI therapy and with vaccination in multiple tumor models and mouse strains, accompanied by dramatically increased systemic and intratumoral CD8+ T-cell responses. Here, NKTR is linked to neoplasm.